BioReference is a laboratory medical practice, humanizing and streamlining the process between data and diagnosis. With our leading position in genetics, women’s health and cancer, as well as our academic collaborations, we are advancing the course of modern medicine. Our specialized brands and laboratories are a testament to our innovation:

Our GenPath Oncology division was founded at BioReference in 2000; it focuses on providing a comprehensive test menu to oncologists and pathologists. Services offered by our GenPath Oncology division include morphological analysis, immunohistochemistry, FISH, flow cytometry, karyotyping, molecular analysis and next generation sequencing. GenPath serves more than 1,000 oncologists across the United States and was recognized by Frost and Sullivan as the 2012 Cancer Diagnostic Company of the Year.  Our GenPath division maintains a strategic advantage in relation to other diagnostic laboratories that revolves around three key areas: clinical expertise, scientific innovation and cost effectiveness.

Our GenPath Women’s Health division offers a complete menu of tests for the OB-GYN and women’s health providers. Since its inception in 2005, BioReference’s GenPath Women’s Health division has risen to become one of the premier specialty labs in the country, including the development of an innovative technology platform for sexually transmitted and other vaginal infections, pan-ethnic carrier testing and maternal risk assessment and prenatal diagnosis. Our GenPath division has grown and evolved to become the One Lab for every phase of a patient’s life, offering solutions to all women’s health testing and service needs. In 2015, GenPath launched an industry-leading line of hereditary cancer testing.

 

GeneDx, Inc. is a global leader and pioneer in advanced genetic and genomics testing, providing specialized services to patients and their families in over 55 countries for nearly 20 years.  Established in 2000 by researchers from NIH, the company has evolved to become one of the largest, most innovative patient-focused companies in the world.  Led by its renowned whole exome sequencing program, and an unparalleled comprehensive genetic testing menu, GeneDx has a continued expertise in rare disorders, as well as one of the broadest menus of sequencing services available, including diagnostic testing for hereditary cancers, metabolic, cardiac, mitochondrial, neurological, ophthalmology, prenatal diagnostics and targeted variant testing. GeneDx continues to be a trusted global partner with healthcare providers. Through clinical and research collaborations, GeneDx has identified and published new disease causing genes, including more than five-dozen in the last three years alone, aiding in the advancement of genomics.

Our Laboratorio Buena Salud division was launched in 2012 as the first nationwide laboratory service dedicated exclusively to Spanish-speaking providers and patients. It was developed to improve access to care and quality of care by assisting physicians who treat patients in predominantly Hispanic communities. This division of our laboratory operations ushers in a new level of service to a traditionally underserved segment of the country’s population, where disparities in healthcare persist for those who do not speak proficient English. All services of the laboratory–including patient care, educational literature, customer service and billing–are provided in Spanish.

BioReference has a network of patient service centers that serves our unique brand entities, including GenPath, Laboratorio Buena Salud and GeneDx. Each patient service center is designed from top to bottom with patient comfort in mind, and courteous and professional phlebotomists are dedicated to delivering a positive experience to each patient.

4Kscore combines four prostate-specific biomarkers with clinical information to provide a male patient with an accurate and personalized measure of his risk for aggressive prostate cancer. The 4Kscore can be used prior to biopsy, or after a negative biopsy, and can predict the likelihood of cancer spreading to other parts of the body in the next 20 years.